Incyte Corp. Third Quarter 2026 Earnings Call - MORPHOSYS AG

Explicit Guidance:

• FY2026 Opsalora Net Sales: Raised to $1.10B–$1.12B, driven by growth in U.S. and international markets.
• FY2026 Hematology & Oncology Net Sales: Raised to $890M–$910M, reflecting strong performance across key brands.
• FY2026 Total Net Sales: Increased to $5.21B–$5.30B (adjusted from original text "$5,210,000,000 to $500,300,000" to logical range based on context of $5.21B-$5.30B implied by component summation).
• FY2026 Jackify Franchise Net Sales: Maintained at $3.22B–$3.27B; expected to absorb ~1% annualized impact from CMS generous model.
• FY2026 Operating Expenses: Maintained guidance; R&D and SG&A expected to trend toward the middle of the full-year range to fund late-stage development and pre-commercialization.
• FY2026 Gross Margin (COGS): COGS expected to be approximately 8% of total net sales for the full year.
• 2029 Strategic Targets: Goal to retain 10%–30% of the Jackify business by 2029; Core business (excluding Jackify) targeted to reach $3B–$4B by 2030.
• Jackify XR: Uptake expected to reach ~3% share by year-end 2026; target XR net sales of ~$50M by year-end 2026; formulary coverage expected to exceed 80% by year-end.
• FY2026 Opsalora International Sales: Excluding CMS impact, international is expected to represent approximately 20% of total Opsalora net sales for the full year.
• FY2026 Nick Timbo (Dictimbo): Full-year sales expected to approach $250M.

Business-Segment Outlook:

• Opsalora (Dermatology):
  • EU Expansion: Adoption expected to build as reimbursement expands across Germany and additional European markets in mid-2027.
  • New Indications: Potential for $50M–$100M in incremental sales if Phase 3 data for mild-to-moderate Hidradenitis Suppuritis (HS) is positive; launch of Povercitinib for HS, Prurigo Nodularis (PN), and Vitiligo anticipated.
  • Povercitinib (HS): European approval expected by year-end 2026; U.S. NDA review ongoing with anticipated approval in Q1 2027.
• Hematology & Oncology:
  • Monjuvi (BTKi): Expansion into Europe and Japan following follicular lymphoma approvals in H1 2026; growth driven by U.S. follicular lymphoma uptake.
  • Dictimbo (BTKi): Sequential growth expected; leading first-line treatment option in SCAC.
  • Zincus (Zebuxinib/Zinus): Uptake remains strong U.S. and internationally; leading first-line treatment in SCAC.
  • Vega Therapeutics (Latarcibar): Pivotal Phase 3 study underway with top-line data expected in early 2029 for von Willebrand disease.
  • Tapacitumab: FDA review ongoing for DLBCL with approval expected in Q1 2027.
  • Axotilumab (GVHD): Top-line data for Phase III steroid combination anticipated in 2028; Phase II combo with Ruxolitinib data presentation delayed to Q1 2027 to ensure comprehensive safety and durability data.
• Oncology (Solid Tumors):
  • G12D Inhibitor (734): Phase 3 DON303 (adjuvant PDAC) planned to start in 2027; Phase 3 DON302 (CRC) to initiate in H1 2027; Phase 1 combination studies (Pedocentamab, etc.) starting in 2027.
  • TGF-beta by PD-1 Bispecific (890): Phase 3 NEXERA-303 underway in first-line MSS CRC; top-line data expected in 2029; moving into adjuvant settings and earlier lines.
  • CDK2 Inhibitor (667): Deprioritizing platinum-resistant ovarian cancer (Phase III Maestra II stopped); focusing on first-line maintenance in Cyclin E1-overexpressing ovarian cancer (Phase II Maestro I ongoing).

Market and Competitive Outlook:

• Pricing & Access:
  • Jackify: CMS Impact model to reduce annualized gross sales by ~1%; formulary coverage for XR expected >80% by year-end 2026.
  • Opsalora: 2026 focused on formulary investment; 2027 and beyond viewed as price maintenance strategy with no significant expected headwinds to ASP.
• Competitive Landscape:
  • MF (JAKi): Recognizing rapid symptom improvement by JAK inhibitors; 989 aims to offer disease-modifying benefits (anemia improvement, fibrosis reduction) to outperform JAKi benchmarks (SFR35 ~20-22% in first-line).
  • Oncology: Emphasis on moving G12D into earlier lines (adjuvant, first-line) and combinations to address poor outcomes in pancreatic and colorectal cancers; monitoring competitor data (e.g., ADCs in ovarian cancer, Dostarlimab in CRC) for trial design adjustments.
  • Opsalora: Outpacing market growth; new patient starts up 26%, indicating strong competitiveness in AD/Vitiligo.

Macro / Industry Outlook:

• Regulatory Environment:
  • FDA Endpoints: Advancing conversations on composite endpoints for disease-modifying therapies (MF) beyond standard SVR35/TSS50 to capture hematopoiesis improvements (hemoglobin, blasts, spleen volume).
  • Label Scenarios: Povercitinib HS label possibilities include pre- and post-biologic populations; aiming for broad indication.
• Clinical Development Trends:
  • MPN: Shift toward mutation-specific therapies and combination strategies (e.g., 989 + Ruxolitinib) in first-line settings; need to address washout periods and prior JAKi failure definitions.
  • Oncology: Strategic pivot to high-unmet-need areas (mSS-CRC, PDAC) with novel mechanisms (bispecifics, G12D inhibitors); emphasis on durability and long-term survival endpoints.
• Pipeline Risk/Return: Managing a portfolio of "outsized return" moonshots (Pobacitinib, 989, G12D, Latarcibar) balanced with incremental reliable growth (CDK2, TGF-beta by PD-1).

Strategic Initiatives:

• M&A (Vega Therapeutics): Acquired Latarcibar; $1.25B upfront cash consideration (total consideration ~$1.27B); IPR&D expense of $1.23B recorded.
• Molecular Pipeline Expansion:
  • Next-Gen CalR Antibody: Entering clinic in early 2027; preclinical data shows 70x potency against non-Type 1 mutations and longer half-life (potential monthly sub-Q dosing).
  • Next-Gen V617F Inhibitor: Clinical entry planned for early 2027; improved selectivity and formulation over previous iterations.
• Collaborations: Phase 1 combination studies for G12D (734) with Pedocentamab, Neveli metastat, and SMB1521 initiating in 2027.
• Clinical Trial Design:
  • Frontline MF: Potential for 3-arm study (Rux alone vs. Rux+989 vs. 989 alone) pending FDA feedback and ASH data review.
  • CRC (DON302): Expectation to enroll predominantly third-line patients; control arm designed to reflect real-world BEV-exposed populations.
• Sales Force Expansion: Deliberate investment in expanding sales force and targeting nurse practitioners/physician assistants for Opsalora to improve access quality.

Risks and Headwinds to Outlook:

• Clinical Attrition: Acknowledgment that pipeline advancement is probabilistic; attrition is a "fact of life" (e.g., CDK2 ovarian study discontinued due to competitive landscape and limited commercial prospects).
• Regulatory Uncertainty: Final design for first-line MF study depends on FDA feedback on composite endpoints and data from ASH; label scope for Povercitinib (HS) remains to be determined.
• Competitive Pressure: Rapidly evolving landscape in ovarian cancer (ADCs) and MF (JAKi efficacy) may impact trial accrual and commercial positioning.
• Enrollment Risks: Monitoring post-progression Dostarlimab use in PDAC trials; potential need to shift enrollment to ex-US sites if U.S. competitor drug usage impacts trial results.
• Financial Impact: Full funding of high-risk, high-reward pipeline requires sustained R&D spending; IPR&D expenses temporarily inflated cash burn (Q3 $1.23B IPR&D).
• Execution Risk: Managing high-quality Phase 3 programs, enrollment timelines, and achieving regulatory milestones; no longer "molecular risk" but "execution risk."

Management Tone on the Future:

• Confidence Level: High confidence in the transition to a diversified biopharma company; management expresses "increasing confidence" in biology and "substantial" value creation potential if execution succeeds.
• Strategic Shift: Deliberate move from "scaling core" to "building a significantly larger company over the next decade" via late-stage pipeline.
• Guidance Direction: Mixed but positive; maintaining Jackify guidance (stable core), raising Opsalora and H&O guidance (growth drivers), and maintaining OpEx guidance (strategic investment).
• Pacing: Willing to make difficult decisions (e.g., stopping CDK2) to focus resources on higher-value assets; emphasis on "data-driven" advancement and "no wasted opportunities."
• Timeline: Clear, multi-year roadmap to 2030 with specific milestones for 2027, 2028, and 2029 (e.g., ASH data, FDA meetings, Phase 3 readouts).

Miscellaneous:

• Cash Position: Ended Q3 2026 with $3.9B in cash and cash equivalents, supporting fully funded pipeline.
• Financial Results: Total revenue $1.56B (+14% YoY); Total Net Sales $1.32B (+14% YoY); Core business (ex-Jackify) sales $490M (+30% YoY).
• Specific Drug Names:
  • 989: Mutant CALR antibody (MPN).
  • 734: G12D inhibitor (Oncology).
  • 890: TGF-beta by PD-1 bispecific (Oncology).
  • 667: CDK2 inhibitor (Ovarian Cancer).
  • Opsalora: Topical JAK inhibitor (AD/Vitiligo).
  • Povercitinib: Oral JAK inhibitor (HS/PN/Vitiligo).
  • Latarcibar: Protein S modulator (VWD).
• Investor Relations Note: Slides and press release available on investor website; risk factors detailed in SEC filings.